Get the Stockscreener App
19.95
7.23%
1.34
After Hours:
19.85
-0.10
-0.50%
Summit Therapeutics Inc stock is traded at $19.95, with a volume of 2.31M.
It is up +7.23% in the last 24 hours and down -12.09% over the past month.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
See More
Previous Close:
$18.61
Open:
$18.5
24h Volume:
2.31M
Relative Volume:
0.48
Market Cap:
$14.30B
Revenue:
$956.00K
Net Income/Loss:
$-116.03M
P/E Ratio:
-11.87
EPS:
-1.6811
Net Cash Flow:
$-93.84M
1W Performance:
+4.53%
1M Performance:
-12.09%
6M Performance:
+395.16%
1Y Performance:
+1,021%
1-Day Range:
$18.27
$19.98
1-Week Range:
$18.27
$20.18
52-Week Range:
$1.64
$33.89
Summit Therapeutics Inc Stock (SMMT) Company Profile
Name
Summit Therapeutics Inc
Sector
Industry
Phone
650-460-8308
Address
2882 SAND HILL ROAD, MENLO PARK
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-18 | Downgrade | Janney | Buy → Neutral |
| May-02-18 | Initiated | Janney | Buy |
| Apr-12-18 | Reiterated | Needham | Buy |
| Feb-13-18 | Initiated | BTIG Research | Buy |
| Jan-04-18 | Initiated | SunTrust | Buy |
| Dec-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-16-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-05-16 | Reiterated | Needham | Buy |
| Sep-16-16 | Initiated | H.C. Wainwright | Buy |
| Mar-30-15 | Initiated | Needham | Buy |
| Mar-30-15 | Initiated | Oppenheimer | Outperform |
View All
Summit Therapeutics Inc Stock (SMMT) Latest News
The Manufacturers Life Insurance Company Raises Stake in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Trading Down 1.2%Here's What Happened - MarketBeat
Summit Therapeutics Inc (SMMT) Q2 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance UK
Summit Therapeutics Inc (SMMT) Q2 2024 Earnings Call Highlights: Strategic Advances and Financial Insights - GuruFocus.com
Summit Therapeutics (NASDAQ:SMMT) Stock Price Down 1%Time to Sell? - MarketBeat
Squarepoint Ops LLC Acquires 56,614 Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Shares Up 3.7%Still a Buy? - MarketBeat
Summit Therapeutics (NASDAQ:SMMT) Shares Down 1.5%What's Next? - MarketBeat
2 Soaring Stocks That Could Climb Another 112% and 120%, According to Wall Street Analysts - Yahoo Finance
Millennium Management LLC Takes Position in Summit Therapeutics Inc. (NASDAQ:SMMT) - MarketBeat
Summit Therapeutics Inc. (SMMT): Hedge Funds Are Bullish On This NASDAQ Stock Right Now - MSN
Summit Therapeutics Inc. (SMMT): Hedge Funds Are Bullish On This NASDAQ Stock Right Now - Insider Monkey
Summit Therapeutics Inc. (SMMT): Hedge Funds Are Bullish On This NASDAQ Stock Right Now - Yahoo Finance
Summit Therapeutics falls after late-stage data for lead asset - MSN
Is Summit Therapeutics a Millionaire Maker? - Yahoo Finance
(SMMT) Trading Report - Stock Traders Daily
U.S. Dollar Index (DXY) QuotePress Release - The Globe and Mail
Bay Area surfer, Scientologist and billionaire is tackling one of medicine’s toughest problems - MSN
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Summit Therapeutics (NASDAQ:SMMT) Trading Up 0.3%Still a Buy? - MarketBeat
Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market (SMMT) - Seeking Alpha
Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track - MSN
Spirit Airlines, Palantir, Rivian, CVS, Albemarle, Apogee, and More Stock Movers - Barron's
Summit Therapeutics Stock Jumps as Lung Cancer Drug Placed on FDA Fast Track - Yahoo Finance
H.C. Wainwright keeps buy rating on Summit Therapeutics stock, highlighting Fast Track designation - Investing.com
Could Summit Therapeutics Become the Next Merck? - MSN
Spirit Airlines, Palantir, Rivian, Maersk, Summit Therapeutics, CVS, and More Movers - Barron's
Stocks making the biggest moves premarket: Spirit Airlines, Summit Therapeutics, Rivian and more - CNBC
Could Summit Therapeutics Become the Next Merck? - Yahoo Finance
S&P 500 Futures Rise in Premarket Trading; Summit Therapeutics, Axalta Coating Systems Lead - Barron's
Summit completes subject enrolment in Phase III NSCLC treatment trial - Clinical Trials Arena
Is Summit Therapeutics Inc. (SMMT) the Best High Short Interest Stock to Invest In Now? - Insider Monkey
Is Summit Therapeutics Inc. (SMMT) the Best High Short Interest Stock to Invest In Now? - Yahoo Finance
H.C. Wainwright Reiterates Buy Rating on Summit Therapeutics plc (SMMT) - StreetInsider.com
Summit stock jumps as FDA grants fast track tag for lung cancer therapy - MSN
Biggest stock movers Friday: SAVE and SMMT - MSN
Summit stock jumps as FDA grants fast track tag for lung cancer therapy (NASDAQ:SMMT) - Seeking Alpha
Biggest stock movers Friday: SAVE and SMMT - Seeking Alpha
Summit completes subject enrolment in Phase III NSCLC treatment trial - Yahoo Finance
Where Will Summit Therapeutics Be in 3 Years? - sharewise
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC - Business Wire
Where Will Summit Therapeutics Be in 3 Years? - MSN
Where Will Summit Therapeutics Be in 3 Years? - Yahoo Finance
5 stocks that have been short-term winners so far this year - Financial Post
Has Summit Therapeutics Stock Already Peaked? - AOL
Has Summit Therapeutics Stock Already Peaked? - MSN
Serina Therapeutics to Present at the 14th Annual Injectables Summit - Yahoo Finance
Has Summit Therapeutics Stock Already Peaked? - Yahoo Finance
Summit Therapeutics (NASDAQ:SMMT) Trading Down 7% - MarketBeat
Is Summit Therapeutics Stock a Buy? - MSN
Foghorn Therapeutics to Participate in the BMO Oncology Summit - Yahoo Finance
Summit Therapeutics Inc Stock (SMMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Summit Therapeutics Inc Stock (SMMT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Zanganeh Mahkam | Chief Executive Officer |
Mar 26 '24 |
Buy |
3.75 |
30,000 |
112,500 |
30,000 |
| Zanganeh Mahkam | Chief Executive Officer |
Mar 27 '24 |
Buy |
3.72 |
26,000 |
96,720 |
520,814 |
| Dhingra Ankur | Chief Financial Officer |
Mar 26 '24 |
Buy |
3.75 |
100,000 |
375,000 |
354,958 |
| Zanganeh Mahkam | Chief Executive Officer |
Dec 12 '23 |
Buy |
2.07 |
5,000 |
10,350 |
494,814 |
| Dhingra Ankur | Chief Financial Officer |
Dec 13 '23 |
Buy |
2.17 |
20,400 |
44,254 |
254,958 |
| Soni Manmeet Singh | Chief Operating Officer |
Oct 13 '23 |
Buy |
1.68 |
2,976,190 |
4,999,999 |
2,976,190 |
0.76%
0.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):